Zoetis Inc. (NYSE:ZTS) Announces Quarterly Dividend of $0.53

Zoetis Inc. (NYSE:ZTS) declared a quarterly dividend on Thursday, October 8th. Stockholders of record on Friday, October 30th will be given a dividend of $0.53 per share on Tuesday, December 1st. This represents a $2.12 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Friday, October 30th.

Zoetis has raised its dividend by an average of 0.2%annually over the last three years and has increased its dividend annually for the last 14 consecutive years. Zoetis has a dividend payout ratio of 31.0% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Zoetis to earn $6.33 per share next year, which means the company should continue to be able to cover its $2.12 annual dividend with an expected future payout ratio of 33.5%.

Zoetis Stock Up 2.1%

NYSE:ZTS opened at $73.08 on Friday. The stock has a 50-day simple moving average of $73.97 and a 200 day simple moving average of $84.93. Zoetis has a 52-week low of $68.77 and a 52-week high of $148.30. The company has a market cap of $30.20 billion, a PE ratio of 12.04, a PEG ratio of 1.67 and a beta of 0.74. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. The firm had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The business’s revenue was down .2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, sell-side analysts expect that Zoetis will post 6.2 EPS for the current fiscal year.

Institutional Investors Weigh In On Zoetis

Several hedge funds have recently bought and sold shares of the company. J. Stern & Co. LLP lifted its position in Zoetis by 12,431.2% during the fourth quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock worth $3,028,423,000 after acquiring an additional 23,877,416 shares during the last quarter. BlackRock Inc. grew its position in shares of Zoetis by 10.8% in the second quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock valued at $2,833,453,000 after purchasing an additional 3,845,869 shares during the last quarter. State Street Corp increased its stake in shares of Zoetis by 1.8% during the second quarter. State Street Corp now owns 19,667,723 shares of the company’s stock worth $1,413,323,000 after purchasing an additional 343,322 shares during the period. Bank of America Corp DE lifted its holdings in Zoetis by 7.3% during the 1st quarter. Bank of America Corp DE now owns 4,831,652 shares of the company’s stock worth $571,150,000 after purchasing an additional 327,313 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its holdings in Zoetis by 69.6% during the 4th quarter. Janus Henderson Group PLC now owns 3,884,112 shares of the company’s stock worth $488,698,000 after purchasing an additional 1,593,375 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

About Zoetis

Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostics and other products for pets and livestock. Its portfolio is designed to help prevent and treat disease, improve animal health and support veterinary care.

The company serves the companion animal market with products for dogs, cats and other pets, including parasiticides, vaccines, dermatology treatments and pain-management therapies. Zoetis also provides animal health products for cattle, swine, poultry, fish and other livestock, along with diagnostic instruments, tests and services used by veterinarians and producers.

Zoetis was established as an independent public company in 2013 after being separated from Pfizer, which had operated the business as Pfizer Animal Health.